Glioblastoma multiforme (GBM) is the most aggressive type of all primary brain tumors, with an overall median survival o1 year after diagnosis. Despite introduction of multimodal treatment approaches, the prognosis has not improved significantly over the past 50 years. In this study we investigated the effect of intracerebroventricular (ICV) injection of an adeno-associated virus (AAV) vector encoding human interferon-b (AAV-hIFN-b) on glioblastoma growth. Recently, we found that peritumoral parenchymal transduction with an AAV-hIFN-b was exceptionally efficient in eradicating GBM brain tumors. However, the extensive infiltration and migration displayed by glioblastoma cells in patients may leave a significant number of tumor cells outside a local therapeutic zone created by intraparenchymal delivery of AAV vectors. Here we show that pretreatment of mice by ICV infusion of an AAV-IFN-b completely prevents tumor growth in an orthotopic model of GBM. Furthermore, ICV infusion of AAV-IFN-b into mice bearing preestablished U87 intracranial tumors improved their survival compared to mice infused through the same route with a control AAV vector. These data suggest that ICV injection of AAV vectors encoding antitumor proteins is a promising approach deserving further consideration for the treatment of GBM.
Introduction
Glioblastoma multiforme (GBM) is the most aggressive type of all primary brain tumors, with an overall median survival of o1 year for GBM patients. 1 Unfortunately, current multimodal treatment approaches have not improved significantly the prognosis for GBM patients. This dismal clinical picture is the result of a number of features unique to glioblastomas. These include high interstitial fluid pressure and altered vasculature, which limit systemic and local drug delivery to these tumors, 2,3 a large fraction of tumor cells in G 0 at any given time and thus resistance to antimitotic agents, and perhaps the most insidious of all, single-cell invasive growth, which is impossible to identify and target by surgical or radiological means, and ultimately responsible for recurrent tumors that result in the patient's death. Thus, new therapeutic approaches for this devastating disease are needed.
Recently, we have tested a new therapeutic approach for brain tumors using adeno-associated virus (AAV) vectors to genetically modify normal brain parenchyma to create a zone of resistance to tumor growth. We have shown the exceptional effectiveness of this approach consisting of normal brain cells producing an antitumor protein, human interferon-b (hIFN-b), in eradicating tumors in an orthotopic xenograft model of GBM. 4 One of the hallmarks of glioblastomas is single-cell infiltration and extensive migration along white matter tracts and perivascular space of Virchow-Robin. 5, 6 In patients, brain tumor recurrence is for the most part a local phenomenon that occurs after resection within a 2 cm radius around the primary tumor. [7] [8] [9] However, the extensive infiltration and migration displayed by glioblastoma cells in patients may leave a significant number of tumor cells outside a zone of resistance created by intraparenchymal delivery of AAV vectors, even using convection-enhanced delivery, which is highly effective in distributing these vectors over large structures. [10] [11] [12] Furthermore, if the tumor lies near a critical structure in the brain, then intraparenchymal injection of AAV vector close to the tumor may not be an option.
To overcome these potential limitations of intraparenchymal delivery of therapeutic AAV vectors, we hypothesized that intracerebroventricular (ICV) injection of an AAV vector encoding hIFN-b (AAV-hIFN-b), which is secreted from transduced cells, would create a global therapeutic effect against tumor growth through the brain. ICV and intrathecal delivery of AAV2 and AAV4 vectors encoding lysosomal enzymes, which are also secreted from transduced cells, has proven very effective in transducing the normal brain in adult mouse models for lysosomal storage disease, providing therapeutic levels of enzyme throughout the central nervous system. 13, 14 Here, we show that ICV delivery of an AAVhIFN-b is an effective approach to curb glioblastoma tumor growth.
Material and methods

Cell culture
Human glioblastoma cell line U87 (ATCC, Manassas, VA) was cultured in high glucose Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma, St Louis, MO) and 100 U ml À1 penicillin, 100 mg ml À1 streptomycin (Invitrogen) in a humidified atmosphere supplemented with 5% CO2 at 37 1C. U87fluc-mCherry cells stably expressing firefly luciferase (fluc) have been described previously. 4 AAV vector design and preparation The AAV2/rh.8-CBA-IFN-b vector has been previously described. 4 The AAV serotype used in this study is derived from the capsid sequence of AAVrh.8.
15,16 AAV vectors were prepared as described. 17 Animals and stereotaxic injections of mice Intracranial injections were performed in male BALB/c nu/ nu mice age 6-8 weeks obtained from a colony maintained at the Massachusetts General Hospital (MGH). Mice were anesthetized by intraperitoneal injection of ketamine (125 mg kg
À1
) and xylazine (12.5 mg kg À1 ) in 0.9% saline and placed in a rodent stereotaxic frame (Stoelting, Wood Dale, IL). Tumor cells were implanted in the left or right mid-striatum using the following coordinates from bregma in mm: (AP þ 0.5, ML ±2.0, DV À2.5). All tumor cell implantations were performed using a Micro 4 Microsyringe Pump Controller (World Precision Instruments, Sarasota, FL) attached to a Hamilton syringe with a 33-gauge needle (Hamilton Co., Rena, NV). Tumor cells were resuspended in Opti-MEM (Invitrogen) and injected into the striatum in a volume of 2 ml (5 Â 10 5 cells) at a rate of 200 nl min
. After injection, the needle was left in place for 2 min before slow withdrawal. AAV vectors were infused into the left lateral ventricle (coordinates from bregma in mm: AP À0.4, ML þ 1.0, DV À1.7) using a Harvard 22 syringe pump (Harvard Apparatus, Holliston, MA) to drive a gas-tight Hamilton syringe attached to a 33-gauge steel needle (Hamilton Co.) by PEEK tubing (Alltech, Deerfield, IL) and Luer adapters (Amersham Biosciences, Piscataway, NJ). Briefly, 5 Â 10 10 genome copies (gc) or 5 Â 10 11 gc were infused at a rate of 4 ml min À1 after which the needle was left in place for 2 min to prevent backflow before withdrawal. The experimental protocol was approved by the Institutional Animal Care and Use Committee at the MGH and follows guidelines set forth in the National Institutes of Health Guide for the Care and Use of Laboratory Animals. For the survival analysis experiments, animal death was defined as mercy-killing after the development of symptoms associated with tumor burden in accordance with the guidelines of the MGH animal facility.
Bioluminescent imaging
Bioluminescence imaging of tumor-associated fluc expression in live animals was carried out using a cryogenically cooled, high-efficiency CCD camera system (Roper Scientific) available to us through the MGH Small Animal Imaging Facility at the Center for Molecular Imaging Research as described. 4 hIFN-b level in brain lysates by ELISA Quantification of hIFN-b in tissue lysates was performed using the hIFN-b enzyme-linked immunosorbent assay (ELISA) kit (PBL Biomedical Laboratories, Piscataway, NJ) according to the manufacturer's instructions. For detection in brain lysates, the mice were killed, the brains removed and placed in a mouse coronal matrix (Roboz Surgical Instrument Co., Gaithersburg, MD) for sectioning. An approximately 2 mm brain slice was removed spanning the region of striatum corresponding to where tumor cells were implanted in therapeutic efficacy experiments (coordinates: AP þ 0.5, ML±2.0, DVÀ2.5). The striatum was further isolated by careful cutting with a scalpel, and the tissue was placed in 400 ml mammalian protein extraction reagent lysis buffer (Pierce, Rockford, IL) containing Complete Protease Inhibitor Cocktail (Roche, Indianapolis, IN). The tissue was first homogenized and then rotated at 4 1C for 15 min. The lysate was then centrifuged for 5 min at 16 000 g. Clarified lysate was transferred to a fresh tube. Protein concentrations were determined using the DC protein assay (Bio-Rad, Hercules, CA). Lysates were diluted 1:1000 in dilution buffer before the ELISA. The sensitivity of the assay was 25 ng hIFN-b per ml.
Hematoxylin and eosin staining
To visualize tumor tissue in brain sections of mice, hematoxylin and eosin (H&E) staining was performed according to standard protocols on 20 mm brain slices. High-resolution images of the stained sections were obtained using a Nikon Super Coolscan 9000 and Nikon Scan 4.0 imaging software (Nikon, Melville, NY).
Vector distribution analysis
To analyze AAV vector distribution, AAV2/rh.8-CBA-GFP-injected mice were perfused with 4% paraformaldehyde 2 weeks after vector infusion. The brain tissue was sectioned into 50 mm coronal sections, coverslipped with Fluorescence Mounting Media (Dako North America, Carpinteria, CA) and visualized with a Nikon Eclipse TE2000-U fluorescence microscope. Images were captured with a Retiga EXi CCD digital camera (QImaging, Surrey, British Columbia, Canada) and viewed with Metavue Imaging Software (version 6.2r4; Molecular Devices Corp., Downingtown, PA).
Statistical analysis
Data presented provide the mean value ± 1 standard deviation. Group comparisons were computed by an unpaired Student's t-test and one-way analysis of variance using GraphPad Prism Software (version 5.0; San Diego, CA). For statistical analysis of group comparisons in Kaplan-Meier survival curves, the log-rank (MantelCox) test and log-rank test for trend were performed using GraphPad Prism Software.
Results
Striatal expression of hIFN-b after ICV delivery of AAV vector in adult athymic nude mice
On the basis of the therapeutic efficacy of ICV infusion of AAV vectors encoding a secreted protein in adult mice, 13 we hypothesized that ICV delivery of an AAV-hIFN-b in adult mice may be an effective approach to control and prevent brain tumor growth in an experimental GBM model. Our first goal was to determine hIFN-b levels in brain parenchyma after infusion of 5 Â 10 10 gc of AAV2/ rh.8-CBA hIFN-b (AAV-hIFN-b), or AAV-ev (vector without a transgene), into the left cerebral ventricle of 6-to 8-week-old athymic nude mice. Two weeks after infusion we found comparable levels of hIFN-b (approximately 3 ng mg À1 total protein) in ipsilateral and contralateral striatum of mice injected with AAV-hIFN-b (Figure 1 ).
Pretreatment of adult athymic nude mice with AAV-hIFN-b vector infused ICV prevents brain tumor growth
To test our hypothesis, we infused 5 Â 10 10 gc of AAV-hIFN-b into the left cerebral lateral ventricle of 6-8-week-old athymic nude mice, and 2 weeks later we injected 5 Â 10 5 U87fluc-mCherry cells into the ipsilateral or contralateral striatum (Figure 2a) . Control mice injected ICV with 5 Â 10 10 gc of AAV-ev vector received 5 Â 10 5 U87fluc-mCherry cells in the ipsilateral striatum. We assessed tumor growth by sequential in vivo imaging of tumor-associated bioluminescent signal (TABS) (Figures 2b and c) . TABS in AAV-hIFN-b-treated mice was detectable in the first two imaging sessions at day 3 and 7 post-tumor injection, albeit lower than in controls, and was absent in both groups of animals from 2 weeks on (Figure 2b) . In contrast, TABS in AAV-ev-treated animals was detectable at 2 weeks post-tumor injection (Figure 2b) , and continued to increase until the last imaging session at 4 weeks post-tumor injection (Figure 2c ). The end point in these studies was defined as a body weight loss 420% of maximal body weight. All AAV-hIFN-b-treated mice survived until the arbitrary end point at 80 days post-tumor injection, which is significantly longer (Po0.01) than the median survival of AAV-ev-treated animals (35 days, Figure 2d ). Histological analysis of brain sections from representative animals showed large tumors in control animals treated with AAV-ev, and no evidence of tumors in AAV-hIFN-btreated animals (Figure 2e ).
ICV delivery of AAV-hIFN-b in athymic nude mice with preexisting tumors improves survival Next we analyzed whether this delivery modality was effective in controlling the growth of established glioblastoma tumors. We injected 5 Â 10 5 U87fluc-mCherry glioma cells into the left or right striatum of 6-to 8-weekold athymic nude mice. One week after tumor cell implantation, we infused 5 Â 10 10 gc of AAV-hIFN-b into the left ventricle. Control mice received 5 Â 10 11 gc of AAV-ev (Figure 3a) . At 1 and 3 weeks after vector injection, TABS was three-and fourfold higher in control mice compared to those treated with AAV-hIFN-b contralateral or ipsilateral to the tumor, respectively (at 1 week P ¼ 0.11 and 0.17, at 3 weeks P ¼ 0.14 and 0.20; Figure 3b ). In addition we tested the antitumor effect of a higher dose of AAV-hIFN-b vector (5 Â 10 11 gc) injected contralateral to tumor (Figure 3b) . At 1 week after vector injection the higher dose resulted in statistically significant lower TABS compared to the control and low-dose groups (B30-fold, P ¼ 0.03; Figure 3b ). Within 2 weeks after AAV-hIFN-b vector infusion, no bioluminescence signal was detectable in any of the mice in this high-dose group (Figures 3b and c) . All mice in the control group treated with AAV-ev were killed within 6 weeks posttumor injection (median survival 37 days, Figure 3d) . Some of the low-dose animals survived longer than the animals in the control group, although this was not statistically significant (median survival 35 (ipsilateral) and 45 (contralateral) days, P ¼ 0.6 and 0.2 respectively, (Figure 4a ). In the injected hemisphere GFP-positive cell bodies were detected in the cortex along the needle track (Figure 4a, left) , as well as in the ependymal lining of the ventricles (Figure 4b ), subventricular zone (Figure 4c ) and septum (Figure 4a, left; Figure 4d ). In addition, intense GFP signal was seen in glial cells located in the corpus callosum (Figure 4e ). GFP-positive cells were also present in cortical layer VI (Figure 4f ). Pyramidal neurons in the CA1 region of the ipsilateral hippocampus were also transduced, but in a declining anterior-posterior gradient (Figures 4g and h) . Some pyramidal cells in the posterior ipsilateral CA3 region were also detected (Figure 4i ). The hippocampal oriens and radiatum layers of the ipsilateral and contralateral hippocampi were filled with GFP fibers (Figure 4a, right) . The latter observation is consistent with the intense GFP signal observed in the fornix (Figure 4a , center) composed of commissural collaterals that connect both hippocampi. In the contralateral hemisphere, GFP-positive cells were detected only in the septal nuclei close to the midline (Figure 4a, left) .
Discussion
In this study we analyzed the antitumor efficacy of ICV infusion of an AAV-hIFN-b in an experimental orthotopic GBM model. A significant antitumor effect (measured by both tumor-associated bioluminescent imaging and survival analysis) was observed against U87 tumors injected intracranially before or after AAV vector infusion. To our knowledge, this is the first study showing that ICV infusion of an AAV vector carrying a (Figure 2 ). In addition, ICV injection of the same vector into U87 tumor-bearing nude mice resulted in a significant survival advantage compared to controls, although AAV-hIFN-b-treated mice were eventually killed because of 420% body weight loss related to disease progression (Figure 3d ). Previously we showed that transduction of peritumoral normal brain with AAV vectors encoding hIFN-b under a neuronalspecific promoter, or a ubiquitous promoter (CBA promoter as in this study), resulted in complete regression of established glioma tumors and 100% survival (Maguire et al., unpublished observations). 4 The difference in efficacy between this and our previous study may be due to the local concentration of hIFN-b at the brain/ tumor interface. Evidence for this is the fact that the concentration of hIFN-b in the striatum (same coordinates used for tumor implantation) after intrastriatal injection of AAV-hIFN-b (10 11 gc) was B29-fold higher than that obtained in the current study using ICV-injected AAV-hIFN-b (5 Â 10 10 gc; Figure 1 ). Furthermore, increasing the dose of ICV-delivered AAV-hIFN-b from 5 Â 10 10 to 5 Â 10 11 gc increased the survival time significantly (Figure 3 ). Interestingly in high-dose mice, tumor-associated bioluminescence was undetectable by 2 weeks, and remained so until at least 3 weeks after vector infusion. Nonetheless all high-dose AAV-treated mice ultimately succumbed to tumor growth (determined by histological examination of brain sections, Supplementary Figure S1 ). This indicates that the highest vector dose was insufficient to generate hIFN-b levels necessary to eliminate all U87 tumor cells. Most likely the rapid loss of bioluminescent signal indicated that the majority of the tumor mass was eliminated by IFN-b. In all likelihood a small number of tumor cells below the detection limit of intracranial imaging survived due to higher resistance to relatively low levels of hIFN-b, and eventually formed a tumor. It has been shown that subpopulations of tumors can gradually circumvent anti-angiogenic therapy in vivo after an initial rapid regression. 18 Higher vector doses could potentially eliminate all tumor cells leading to longterm survival of all treated animals.
The moderately low levels of hIFN-b in brain parenchyma are most likely due to the relatively low number of AAV-transduced cells in the brain after ICV delivery of AAV vector in adult athymic nude mice (Figure 4) . Most transduced cells were located in the hippocampal formation and corpus callosum. Therefore, distribution of hIFN-b to the contralateral striatum is likely to have occurred by cerebral spinal fluid (CSF) flow in the perivascular space of Virchow-Robin. Others have shown that recombinant or vector-encoded lysosomal enzymes can be distributed efficiently throughout the dog and mouse brain by the CSF. 13, 19, 20 The limited transduction reported here in adult mice is in contrast to the exceptional widespread transduction of the brain after ICV delivery of the same AAV vector serotype in neonatal C57BL/6 mice. 17 It is important to note, however, that in AAV-GFP-injected animals, GFP distribution is restricted to the cell bodies, dendrites and axons of AAV-transduced cells. hIFN-b distribution in the brain is likely to be much broader than GFP as IFN-b is a secreted protein (much like the secreted lysosomal enzymes in the aforementioned studies), which could be distributed by diffusion, and CSF flow. Evidence for this comes from the observation that detectable levels of hIFN-b were found in striatum (same site as for tumor implantation) after ICV injection of AAVrh.8-hIFN-b whereas no GFP-positive cells were detected in this same region when AAVrh.8-GFP was injected ICV. The key to achieving a robust antitumor effect using the present strategy is to transduce large number of cells, preferentially those lining the ventricles after ICV delivery of AAV vectors. Given the minimal levels of transduction of these regions of the brain using AAV-rh.8 after ICV delivery, another alternative may be to use an AAV4 vector to deliver the therapeutic gene. AAV4 vectors have been shown to transduce ependymal cells very efficiently after ICV delivery in adult mice, and they have been used to achieve therapeutic levels of a lysosomal enzyme throughout the entire brain. 13 A number of parameters are likely to determine the final parenchymal concentration of recombinant proteins secreted into the CSF from vectortransduced ependymal cells such as their size, interactions with extracellular matrix components, cellular receptor densities and half-life. Although many of these parameters are likely to be different between lysosomal enzymes and hIFN-b, we anticipate that ICV infusion of an AAV4 hIFN-b vector would result in considerably higher hIFN-b levels in brain parenchyma than obtained with the vector used in this study because of higher transduction efficiency and secretion of hIFN-b directly into CSF in the lateral ventricles. Nonetheless, even with relatively low levels of transduction in the brain with ICV administered AAVrh.8, we show proof of concept that ICV injection of a viral vector encoding an antitumor protein is a viable approach for controlling brain tumors.
Distribution of high levels of IFN-b throughout the brain by CSF could have potential risks given the pleiotropic nature of this cytokine. [21] [22] [23] The absence of serious side effects in the present study could be misleading because hIFN-b has low affinity for murine interferon receptors. 24 Additional studies using AAV vectors encoding mouse IFN-b will be necessary to assess safety and may indeed dictate that this type of therapeutic approach be implemented for relatively short periods of time. This would require the use of AAV vectors capable of drug-regulated gene expression, [25] [26] [27] [28] or IFN-b activation of protein kinase R may decrease translation of AAV-encoded IFN-b mRNA. 29 Further development of the global therapeutic approach investigated here may allow complete eradication of established tumors in mice. Scaling up the ICV injection that gave a therapeutic effect against established tumors 1000-fold for the human brain would result in a dose of 5 Â 10 14 , which is achievable by today's vector production capabilities (B10 15 gc per ml). At these titers, B500 ml would be injected into the ventricle, which is an accepted volume. Although the dose of AAV vector will be readily achieved in terms of vector production and injection volume, the limiting factor will be toxicity of IFN-b as mentioned above. Still, subtherapeutic amounts of ICV-administered AAV-IFN-b may enhance tumor cells' sensitivity to apoptosis by other agents (for example, radiation, sTRAIL). This approach is most likely to provide maximal therapeutic benefit when used as a complementary modality following surgical debulking and injection of the AAV-hIFN-b into the peritumoral brain. 4 The ICV delivery route of AAV vectors may also be the only means of efficient transduction when tumor is located in an inoperable region of the brain (for example, brain stem). AAV vector-mediated CSF production of antitumor proteins could be used to prevent/delay the growth of glioblastoma cells that infiltrate normal brain tissue, migrate away from the main tumor mass and give rise to tumor recurrences that are nearly impossible to treat with current postsurgical radiation and chemotherapeutic regimens.
